Journal
AMERICAN JOURNAL OF TRANSPLANTATION
Volume 9, Issue 11, Pages 2459-2465Publisher
WILEY
DOI: 10.1111/j.1600-6143.2009.02819.x
Keywords
Antibody-mediated rejection; endothelium; endothelial cells; signal transduction; transplantation
Categories
Funding
- National Institute of Allergy and Infectious Diseases [RO1 AI 42819]
- NIH [U01AI077821]
- National Heart Lung and Blood Institute [RO1 HL 090995]
Ask authors/readers for more resources
Patients developing posttransplant antibodies against HLA and non-HLA antigens expressed by the endothelium of the graft undergo more frequent episodes of rejection and have decreased long-term graft survival. Antibodies against the endothelium can alter/damage the cells of the graft through several mechanisms. Historically, antibodies were thought to elicit endothelial cell injury via complement-dependent mechanisms. New research has shown that antibodies can also contribute to the process of transplant rejection by stimulating proinflammatory and proproliferation signals. Antibody ligation leads to several functional alterations in EC including Weibel Palade body exocytosis, leukocyte recruitment, growth factor expression and cell proliferation. In contrast, under certain circumstances, antibodies may induce prosurvival signals and graft accommodation. The signaling events regulating accommodation vs. rejection appear to be influenced by the specificity and concentration of the anti-HLA antibody and the degree of molecular aggregation. Knowledge of the HLA and non-HLA antibody-mediated signaling pathways has the potential to identify new therapeutic targets to promote accommodation and prevent acute and chronic antibody-mediated rejection.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available